Kybella — Competitive Intelligence Brief

Kybella (DEOXYCHOLIC ACID) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cytolytic Agent [EPC]. Area: Other.

marketed Cytolytic Agent [EPC] G-protein coupled bile acid receptor 1 Other Small molecule

Target snapshot

Kybella (DEOXYCHOLIC ACID) — AbbVie. Kybella works by targeting and destroying excess fat cells through a process that involves disrupting the cell membrane.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Kybella TARGET	DEOXYCHOLIC ACID	AbbVie	marketed	Cytolytic Agent [EPC]	G-protein coupled bile acid receptor 1	2015-01-01
Cholbam	CHOLIC ACID	Mirum	marketed	Bile Acid [EPC]	G-protein coupled bile acid receptor 1	2015-01-01
Prelone	prednisolone	Generic (originally Schering)	marketed	Glucocorticoid (corticosteroid)	Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1	1955-01-01
Cholbam	Cholbam	Mirum Pharmaceuticals, Inc.	marketed		G-protein coupled bile acid receptor 1, Bile acid receptor
prednisolon	prednisolon	Hannover Medical School	marketed		Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1
Kybella	Kybella	Massachusetts General Hospital	marketed		G-protein coupled bile acid receptor 1, fMet-Leu-Phe receptor, Bile acid receptor
Doxycycline and tauroursodeoxycholic acid	Doxycycline and tauroursodeoxycholic acid	Fondazione IRCCS Policlinico San Matteo di Pavia	phase 3	Combination therapy (antibiotic + bile acid derivative)	Matrix metalloproteinases, FXR (farnesoid X receptor), TGR5 (G-protein coupled bile acid receptor 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cytolytic Agent [EPC] class)

1. AbbVie · 1 drug in this class